<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612143</url>
  </required_header>
  <id_info>
    <org_study_id>NP28327</org_study_id>
    <secondary_id>2012-001001-24</secondary_id>
    <nct_id>NCT01612143</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Cross-over Study to Investigate the Relative Bioavailability of Setrobuvir (STV) Tablet Formulation Versus the Reference Setrobuvir Capsule Formulation Following Oral Administration With or Without a High Fat Meal in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, randomized, single dose, 4-sequence, 4-period crossover study will assess
      the relative bioavailability of setrobuvir as tablet formulation versus the reference capsule
      formulation in healthy volunteers. Subjects will be randomized to one of four treatment
      sequences receiving 4 single oral doses of 200 mg setrobuvir, either as tablet or capsule
      formulation with or without a high fat meal, with a washout period of at least 14 days
      between treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability: Cmax/area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 168 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A: STV capsule (after high fat meal)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: STV capsule (fasted state)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C: STV tablet (after high fat meal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D: STV tablet (fasted state)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>setrobuvir</intervention_name>
    <description>200 mg capsule formulation, single oral dose</description>
    <arm_group_label>A: STV capsule (after high fat meal)</arm_group_label>
    <arm_group_label>B: STV capsule (fasted state)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>setrobuvir</intervention_name>
    <description>200 mg tablet formulation, single oral dose</description>
    <arm_group_label>C: STV tablet (after high fat meal)</arm_group_label>
    <arm_group_label>D: STV tablet (fasted state)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female adults, 18 to 55 years of age inclusive

          -  Body mass index (BMI) 18.0 - 30.0 kg/m2

          -  Healthy status defined as absence of clinically significant acute or chronic condition
             as determined by complete medical history and physical examination

          -  Females of childbearing potential and males and their female partner(s) of
             childbearing potential must agree to use 2 forms of contraception as defined by
             protocol during treatment and for at least 3 months after the last dose of study drug

          -  Non-smokers or use of &lt; 10 cigarettes (or equivalent nicotine-containing product) per
             day

          -  Negative results on following screening laboratory test: urine drug screen, urine
             alcohol screen

          -  Willing and able to consume the study-specified meal on day of dosing

        Exclusion Criteria:

          -  Pregnant or lactating women, or males with female partners who are pregnant or
             lactating

          -  History of current alcohol abuse and/or other drug addiction &lt;/= 2 years prior to
             enrollment in the study

          -  Participation in other clinical studies within 60 days prior to study randomization

          -  Positive for hepatitis B, hepatitis C or HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

